A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
CA001-044
Phase 2 other active
Quick answer
A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer for Extensive-Stage Small Cell Lung Cancer is a Phase 2 program (other) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- other
- Status
- active